Robin Custeau
Principal Analyst
USA
15+ years of experience
Robin covers metabolic/Endocrinology and Cardiovascular clinical trials for the following diseases: Anemia, Bone Fracture Healing, Constipation, Diabetic Complications, Functional Dyspepsia, Gastroparesis, GERD, Growth Disorders, Hyperkalemia, Hyperuricemia/Gout, Hyponatremia, Lysosomal Storage Disorders, Obesity, Osteoporosis, Renal Disease, Sickle Cell Disease, Thalassemia, Type 1 Diabetes, Type 2 Diabetes, Acute Coronary Syndromes, Arrhythmia, Congestive Heart Failure, Coronary Artery Disease, Dyslipidemia, Hemostasis/Hemophilia, Hypertension, Peripheral Arterial Disease, and Thrombotic Disorders.
She joined Informa in 2007. In her current role, her areas of expertise are clinical trials for Metabolic/Endocrinology and Cardiovascular diseases, as well as the drugs in development for these diseases.
Robin previously worked for Perceptive Informatics as a Lead Imaging Research Associate for clinical trials. She also worked at Quintiles as a Research Associate and remotely monitored clinical trial study sites.
Her greatest achievement and development as an analyst was being promoted to Principal Analyst this year.
Trialtrove
By Robin Custeau 01 Apr 2017
Given the current limited options and future demand for renal anemia treatment, pharmaceutical companies will have an opportunity to capitalize on this market.
Robin Custeau 03 May 2016
More than half of the 1898 anemia trials in Trialtrove evaluate the treatment or prevention of anemia due to chronic renal disease.
Trialtrove
By Robin Custeau 03 May 2016
More than half of the 1898 anemia trials in Trialtrove evaluate the treatment or prevention of anemia due to chronic renal disease.